## Inotropic Agent Selection in Cardiogenic Shock ### Clinical Context This patient has: - **Hypotension:** BP 85/55 mmHg - **Low cardiac index:** CI 2.0 L/min/m² (normal ≥ 2.5) - **Diagnosis:** Acute decompensated heart failure with cardiogenic shock **Goal:** Increase contractility AND systemic perfusion pressure. ### Correct Statements (Options 0, 1, 3) **Option 0 — Dobutamine vs. Dopamine (Correct):** | Agent | Mechanism | Effect on SVR | Use in Cardiogenic Shock | |---|---|---|---| | **Dobutamine** | β1-selective (+ mild α1) | ↓ or ↔ (vasodilation via β2) | **Preferred** — ↑ inotropy, ↓ afterload | | **Dopamine (high dose > 5 μg/kg/min)** | α1 >> β1 | ↑↑ (vasoconstriction) | Risk of peripheral ischemia | Dobutamine is indeed preferred in cardiogenic shock because it improves contractility without the peripheral vasoconstriction of high-dose dopamine. **Option 1 — Milrinone (Correct):** - Phosphodiesterase-3 inhibitor - **Inotropic effect:** ↑ contractility (via ↑ cAMP) - **Lusitropic effect:** ↑ diastolic relaxation (improves filling) - **Vasodilatory:** ↓ SVR and pulmonary vascular resistance - **Drawback:** Systemic hypotension → often combined with vasopressor (norepinephrine) - Useful in heart failure with elevated filling pressures **Option 3 — Epinephrine Moderate Dose (Correct):** | Epinephrine Dose | β1 Effect | α1 Effect | Net Result | |---|---|---|---| | **Moderate (2–5 μg/kg/min)** | **↑↑ Contractility, HR** | **↑ SVR** | **Inotropy + Vasoconstriction** | At moderate doses, epinephrine combines inotropic support (β1) with vasopressor activity (α1), making it suitable for combined support in cardiogenic shock with hypotension. ### Incorrect Statement (Option 2 — THE ANSWER) **Option 2 — Low-Dose Dopamine (INCORRECT):** The statement claims low-dose dopamine (< 3 μg/kg/min) "selectively activates dopaminergic receptors and causes renal and mesenteric vasodilation **without increasing heart rate or contractility.**" **This is WRONG.** Low-dose dopamine DOES increase heart rate and contractility: | Dopamine Dose | Predominant Receptor | Cardiac Effects | Vascular Effects | |---|---|---|---| | **Low (< 3 μg/kg/min)** | **DA > β1** | **↑ HR, ↑ contractility** | Renal/mesenteric vasodilation | | **Moderate (3–5 μg/kg/min)** | **β1 >> DA** | **↑↑ Contractility, ↑ HR** | Mild vasoconstriction | | **High (> 5 μg/kg/min)** | **α1 >> β1** | Tachycardia, arrhythmias | ↑↑ Vasoconstriction | **The error:** At low doses, dopamine activates both dopaminergic receptors (renal vasodilation) AND β1-adrenergic receptors (increased contractility and heart rate). It does NOT selectively activate dopaminergic receptors "without increasing heart rate or contractility." **Key Point:** **Low-dose dopamine (< 3 μg/kg/min) = dopaminergic + β1 effects. It DOES increase contractility and heart rate, not just renal perfusion.** **High-Yield:** Dopamine dose-response is a classic NEET PG board question: - **Low (< 3):** DA + β1 → renal vasodilation + inotropy - **Moderate (3–5):** β1 >> DA → strong inotropy + vasoconstriction - **High (> 5):** α1 >> β1 → pure vasoconstriction **Clinical Pearl:** The concept of "renal-dose dopamine" (2 μg/kg/min) for renal protection in shock is now **controversial and largely abandoned** in modern critical care. Low-dose dopamine still causes tachycardia and arrhythmias without proven renal benefit. **Mnemonic:** **D-A-B rule for dopamine:** - **D**opamine (low) → **D**opaminergic + β1 - **A**lpha (high) → **A**lpha-1 dominant - **B**eta (moderate) → **B**eta-1 dominant
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.